Results 51 to 60 of about 2,929 (206)

Impact of Cytochrome P450 Enzymes on the Phase I Metabolism of Drugs [PDF]

, 2023
The cytochrome P450 (CYP) enzyme family is the major enzyme system catalyzing the phase I metabolism of xenobiotics, including pharmaceuticals and toxic compounds in the environment.
Alessia Catalano, Carmela Saturnino, Domenica Scumaci, Domenico Iacopetta, Elisabetta Scali, Jessica Ceramella, Maria Stefania Sinicropi, Michele Pellegrino, Stefano Aquaro   +8 more
core   +2 more sources

Clinical backgrounds and outcomes of patients with Barrett's esophageal adenocarcinoma treated via endoscopic submucosal dissection in Kyushu, Japan: A retrospective multicenter cohort study

DEN Open, Volume 6, Issue 1, April 2026.
Abstract Objectives Most esophageal cancers in Japan are squamous cell carcinomas; however, there has been some concern regarding a recent increase in Barrett's esophageal adenocarcinoma (BEA). This study aimed to clarify the clinical characteristics and outcomes of patients treated via endoscopic submucosal dissection (ESD) in Kyushu, including ...
Fumisato Sasaki, Kazuhiro Mizukami, Taro Akashi, Naoyuki Yamaguchi, Ryosuke Gushima, Hideaki Miyamoto, Shohei Uehara, Yoichiro Ono, Takashi Hisabe, Yuzuru Kinjo, Yuichiro Nasu, Kensuke Fukuda, Taisuke Inada, Yorinobu Sumida, Takashi Akutagawa, Tadashi Miike, Sho Suzuki, Hiroki Fukuya, Michita Mukasa, Mitsuru Esaki, Shinsuke Kumei, Yosuke Minoda, Tetsu Kinjo, Daisuke Yamaguchi, Yoshio Fukuda, Kazutoshi Hashiguchi, Hiroki Yano, Hiroshi Fujita, Ryo Shimoda, GI‐Kysuhu study group   +29 more
wiley   +1 more source

Vonoprazan – A Potassium-Competitive Acid Blocker: An Overview [PDF]

Vonoprazan helps in management and treatment of heartburn, peptic ulcers and gastroesophageal reflux disease. The structure,mechanism of action, and clinical applications have been discussed in this article.
Dr Jyoti Yadav, Dr SHUBHRICA
core   +5 more sources

In Vitro and In Vivo Rat Model Assessments of the Effects of Vonoprazan on the Pharmacokinetics of Venlafaxine

Drug Design, Development and Therapy, 2020
Feifei Chen,1,* Hui Jiang,1,* Jia Xu,1 Shuanghu Wang,1 Deru Meng,1 Peiwu Geng,1 Dapeng Dai,2 Quan Zhou,1 Yunfang Zhou1 1The Laboratory of Clinical Pharmacy, The Sixth Affiliated Hospital of Wenzhou Medical University, The People’s Hospital of ...
Chen F, Jiang H, Xu J, Wang S, Meng D, Geng P, Dai D, Zhou Q, Zhou Y   +8 more
doaj  

Vonoprazan and high‐dose amoxicillin dual therapy for Helicobacter pylori first‐line eradication: A single‐arm, interventional study

JGH Open, 2023
Background To date, no interventional trial has assessed the efficacy and safety of vonoprazan and high‐dose (500 mg four times daily, 2000 mg/day) amoxicillin dual therapy in terms of Helicobacter pylori eradication.
Soichiro Sue, Masaaki Kondo, Takeshi Sato, Hiroyuki Oka, Katsuyuki Sanga, Tsuyoshi Ogashiwa, Mao Matsubayashi, Hiroaki Kaneko, Kuniyasu Irie, Shin Maeda   +9 more
doaj   +1 more source

Helicobacter pylori: types of diseases, diagnosis, treatment and causes of therapeutic failure [PDF]

, 2016
Acute upper gastrointestinal lesions have a multifactorial etiology but, regardless of the cause, they are related to mucosal barrier destruction. Since Helicobacter pylori induces a superficial chronic gastritis with the infiltration of neutrophils in ...
Ciorbagiu, Mihai Calin, Mirea, Cecil Sorin, Moraru, Emil, Obleaga, Cosmin Vasile, Valcea, Ionica Daniel, Vere, Cristin Constantin   +5 more
core   +3 more sources

Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations [PDF]

, 2016
This review provides an update on the pharmacokinetic properties of vonoprazan and their correlates with pharmacodynamics; preliminary data on the therapeutic efficacy of vonoprazan as compared to lansoprazole in GERD patients Expert opinion: At variance
Blandizzi, Corrado, Bodini, Giorgia, de Bortoli, Nicola, Furnari, Manuele, Marabotto, Elisa, Martinucci, Irene, Moscatelli, Alessandro, Pellegatta, Gaia, Romana, Chiara, Savarino, Edoardo, Savarino, Vincenzo   +10 more
core   +1 more source

Effect of Vonoprazan on Delayed Bleeding after Endoscopic Submucosal Dissection for Gastric Neoplasia among Antithrombotic Drug Users: A Single-Center, Single-Arm Prospective Observational Case Control Study [PDF]

, 2020
Antithrombotic therapy is a major risk factor for delayed bleeding after endoscopic submucosal dissection (ESD) for gastric neoplasia. A potassium-competitive acid blocker, vonoprazan, is expected to prevent delayed bleeding better than conventional ...
Doi, Akira, Matsueda, Kazuhiro, Mizuno, Motowo, Mouri, Hirokazu, Nishimura, Naoyuki, Okada, Hiroyuki, Shimodate, Yuichi, Takayama, Hiroshi, Takezawa, Rio, Yamamoto, Shumpei   +9 more
core   +1 more source

Antireflux myoplasty: Endoscopic myoplasty with bilateral sling fiber plication for refractory gastroesophageal reflux disease

DEN Open, Volume 6, Issue 1, April 2026.
Abstract Endoscopic antireflux therapy is a novel endoscopic treatment for refractory gastroesophageal reflux disease. We developed antireflux myoplasty (AR‐MP), a modified version of antireflux mucoplasty (ARM‐P), in which exposed bilateral sling fibers are sutured directly via endoscopic hand‐suturing.
Hironari Shiwaku, Akio Shiwaku, Hisatoshi Irie, Takayuki Akasaki, Seiya Sato, Nobuhiko Koreeda, Katsudai Shirakabe, Kosuke Yamauchi, Haruhiro Inoue, Suguru Hasegawa   +9 more
wiley   +1 more source

Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date

Therapeutic Advances in Gastroenterology, 2018
Potassium-competitive acid blocker (P-CAB) is a class of drug that competitively blocks the potassium-binding site of H + , K + -adenosine triphosphate (ATP)ase. Although the history of this class of drugs started over 30 years ago, clinical use of two P-
Kentaro Sugano
doaj   +1 more source